GC Therapeutics is using synthetic biology to program patients' cells into any cell type. Engineering the identity of a cell has a lot of potential as a new therapeutic modality as well as for cell therapies, transplants and testing new drugs. GCTx’s approach involves reprogramming patient-derived stem cells to make various cell types by discovering novel cell-differentiation recipes. The aim is to make this approach both efficient and scalable by dictating cell fates in a single step. In addition, GCTx is developing SuperCellsTM by tailoring cells for specific diseases.

GC Therapeutics

Scientist - Assay Development

Scientist / Senior Scientist - Immunology

Scientist / Senior Scientist - Process Development

Research Associate -  Molecular Biology

George Church spinout gets $65M to ‘revolutionize’ cell therapy - The Business Journals

‘Skin in the game’: Harvard geneticist George Church launches new stem cell company using his own skin cells - The Boston Globe

We're #hiring a new Research Associate - Assay Development in Cambridge, Massachusetts. Apply today or share this post with your network.


  
    GCTx featured by Harvard Medical School
  

We’re excited to share that our CEO, Parastoo Khoshakhlagh, Ph.D., a 2023 Termeer Fellow will be a featured panelist at an upcoming discussion on female leaders in biotech hosted by The Termeer Foundation and WEST - Women in the Enterprise of Science and Technology. This panel will explore the unique experiences, challenges, and successes of women stepping into leadership roles as executives and founders in the biotech industry. Parastoo will be joined by fellow inspiring female leaders Vered Bisker-Leib, Nele Van Dessel (Termeer Fellow), and Jo Viney.

Special thanks to Rachele Ryan, Director of Partnerships at LabCentral for moderating!

📅 Date: November 6, 2024
🕒 Time: 8:00-10:00 AM ET
📍 Location: The Termeer Foundation, 1393 Boylston St., Boston, MA 02215

🔗 Learn more and register at https://lnkd.in/gUSNvzcm

Join us for an empowering conversation that aims to uplift and celebrate women making waves in the world of biotech!

We're #hiring a new Scientist/Senior Scientist - Computational Biologist in Cambridge, Massachusetts. Apply today or share this post with your network.

Proud to announce that our CEO Parastoo Khoshakhlagh, Ph.D. will be speaking on the panel Emerging Technologies and Approaches in Cell & Gene Therapy at #BioFuture2024! 

With the field evolving at an incredible pace, emerging technologies like AI and machine learning are reshaping what we can achieve. She will be joined by Paul Bresge, Kate Rochlin, PhD and moderator Lei Lei Wu to discuss how these innovations are breaking through current limitations, enhancing precision, and speeding up the journey from research to real-world applications. Together, we're making strides toward more effective, accessible therapies that have the power to transform lives. 

Special thank you to Sara Jane Demy, Sara Pinto, and Kimberly Ha for the invitation and opportunity contribute to the discussion and explore the latest topics shaping the future of #healthcare. 

Join us for insightful conversations driving the next wave of breakthrough innovation. Register at www.BioFuture.com!

GC Therapeutics Raises $65M in Series A Funding - FinSMEs

BioFuture 2024: FDA eases the way for cell and gene therapy companies - BioWorld Online

We’re excited to announce our CEO and Co-Founder, Parastoo Khoshakhlagh, Ph.D., will be co-hosting the Boston leg of The Founder-Led Biotech Tour hosted by Pillar VC in Cambridge on Wednesday, November 20th! 

She will be joined by fellow top biotech founders and industry leaders - we hope you can join us to connect with these pioneers and be inspired by the movement.

For more details: https://lnkd.in/gWhS5_4Y

Special thanks to Thomas de Vlaam and Tony Kulesa for making this evening of networking and insights possible!

#PillarVC #CambridgeMA #BostonEvents #Biotech #FounderLedBiotech #Networking #Innovation #BiotechLeaders #GCTx

We're #hiring a new Research Associate, Stem Cell Biology in Cambridge, Massachusetts. Apply today or share this post with your network.

We're #hiring a new Research Associate, In Vivo Biology in Cambridge, Massachusetts. Apply today or share this post with your network.


  
    GCTx technology published in Nature Biotechnology
  

GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space - Pharmaceutical Technology

Wilson Sonsini Advises GC Therapeutics on $65 Million Series A - Wilson Sonsini

A new cell therapy company takes its vision from four founders, and its skin from George Church - STAT

Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News

FDA eases the way for cell and gene therapy companies - BioWorld Online

GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy - Harvard Office of Technology Development

From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech

George Church lab spawns $75m cell therapy startup - Longevity.Technology

George Church launches stem cell programming start-up - Chemical & Engineering News

GCTx: Simplifying iPSC-based cell therapy production - BioCentury

Three SMC STEM Scholars Chosen for Esteemed Fellowship - Santa Monica Mirror

Series A cash for Brenus, GCTx, Nura among week’s VC highlights - BioCentury

We're #hiring a new Research Associate -  Molecular Biology in Cambridge, Massachusetts. Apply today or share this post with your network.


  
    Stem cell startup spun out of George Church’s lab raises $75M
  

Investing in Arda Therapeutics - Andreessen Horowitz

 GC Therapeutics Snares $65 Million Series A 

Stem cell startup spun out of George Church’s lab raises $75M - Endpoints News

Thrilled to have attended BioFuture for the third consecutive year! Last week, at the Cure. in New York City, #BioFuture 2024 gathered a remarkable community of trailblazers, disruptors, and investors from across the healthcare ecosystem to discuss the future of healthcare innovation.

The conference spotlighted impactful discussions on AI/ML, quantum computing, policy advancements, neuroscience, oncology, obesity treatments, longevity, biomanufacturing, cell and gene therapy, cardiovascular health, women’s health, and financing strategies. We explored the convergence of deep tech and deep science in drug discovery & development, diving into the forefront of healthcare transformation.

It was also the perfect opportunity to reconnect with fellow investors, founders, and ecosystem partners. Great to finally meet Parastoo Khoshakhlagh, Ph.D. in person and catch up with Tingting Zhang-Kharas, PhD, Silvia Garcia Codony, and Lynda Chin.

A huge thanks to Sara Jane Demy and Demy-Colton for organizing such an inspiring event. Already looking forward to BioFuture 2025!

#healthcare #biotech #lifescience #biopharma #TechBio #AI #Therapeutics #venturecapital #innovations #deeptech 

Vicebio raises $100m for vaccines and other bio financings - pharmaphorum


  
    GCTx named a finalist for the Harvard Innovation Lab’s 2019 President’s Innovation Challenge
  

Investing in GC Therapeutics - Andreessen Horowitz

 GC Therapeutics Raises $65M in Series A Funding 

 The Week’s 10 Biggest Funding Rounds: Greentech And Biotech See $200M Raises 

GC Therapeutics - The Pharma Letter

GCTx launches with bold cell therapy claim - The Pharma Letter

It is a pleasure for GC Therapeutics to be a part of the Pear VC family and we are very proud that our CEO, Parastoo Khoshakhlagh, Ph.D., has had the unique opportunity to be a part of the amazing community of Persian Founder Circle (PFC). It’s not easy to find so many fantastic, like-minded and driven individuals in one program! 

Big thanks to Mar Hershenson, Pejman Nozad, Eddie Eltoukhy, Roya Soleimani Winner and the PFC team for such an amazing opportunity! If you are a Persian founder (or future founder), don’t miss out on this incredible opportunity.

Context is key: glucocorticoid receptor and corticosteroid therapeutics in outcomes after traumatic brain injury - Frontiers

Investors Flock to Startups Reprogramming Cell Therapies - Labiotech.eu

Vineeta Agarwala - Andreessen Horowitz


  
    ‘Skin in the game’: Harvard geneticist George Church launches new stem cell company using his own skin cells
  


              Stem cell therapy companies take different roads to reproducibility
            

The Week’s 10 Biggest Funding Rounds: Greentech And Biotech See $200M Raises - Crunchbase News


  
    GC Therapeutics is seeking to develop off-the-shelf treatments
  

Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines - BioPharma Dive


  
    GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy 
  


  
    George Church launches stem cell programming start-up
  

The Fed cut rates and biotech stocks… didn’t do much - STAT

GC Therapeutics

Business:

About: